Inflammatory Bowel Disease and Atherosclerosis Development

NCT ID: NCT05781737

Last Updated: 2024-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

115 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2025-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will show the influence of inflammatory bowel disease on the risk of development of atherosclerosis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases Cardiovascular Diseases Inflammation Arterial Stiffness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulcerative colitis

No interventions assigned to this group

Crohn disease

No interventions assigned to this group

Control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inflammatory bowel disease
* Signed informed consent

Exclusion Criteria

* Pregnancy
* Other conditions affecting the prognosis
* Psychiatric disorders affecting the participation in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

I.M. Sechenov First Moscow State Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Olga Mironova

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital #1

Moscow, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Related Links

Access external resources that provide additional context or updates about the study.

https://doi.org/10.38109/2075-082X-2022-4-53-57

Isaikina M.A., Isaev G.O., Pyatigorets E.S., Yurazh M.A., Mironova O.I. Ulcerative colitis and cardiovascular disease. Case report. Systemic Hypertension. 2022;19(4):53-57. (In Russ.)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22-22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CMTS0929 for Inflammatory Bowel Disease
NCT06844708 NOT_YET_RECRUITING EARLY_PHASE1